Healthcare

CG Results offers the skills of an experienced and entrepreneurial healthcare team dedicated to the life sciences sector having closed more than 75 successful transactions to date. Our clients trust us because of our strong international relationships with shareholders and management teams across the healthcare lifecycle. We combine expert financial capabilities with backgrounds in science, healthcare and IT that will bring value to your business.

We work with businesses and entrepreneurs to help articulate the ideal equity story, target the right investors and negotiate the best deal.

• Full service offering for Healthcare M&A transactions, for both buyers and sellers
• Advice on strategic options for healthcare businesses and assets
• Expert guidance on development capital, utilisation of investments or finance for MBO/MBI
• Support for licensing transactions for research assets and marketed products

Healthcare Sub-Sectors

Our highly specialised, global team works together seamlessly across six focus areas in the healthcare sector.

Healthcare Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Feb 2022
has received investment from
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has received investment from
Nov 2021
has invested in
company name confidential

Latest Insights

Reports
23rd November 2022

Pharma Licensing – an introduction

We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process. We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch! Click to […]

Insights
17th October 2022

Pharma Licensing: the why the how and a few things to get right

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Reports
17th October 2022

MedTech Services – Drivers of growth and consolidation

Welcome to our MedTech Services Report. This sets out our views on the tailwinds driving growth and increased outsourcing, an overview of the MedTech CDMO and CRO market as well as the key drivers of consolidation in the sector. We hope that you enjoy this report and look forward to discussing the data and underlying […]